IPA fundamentals
ImmunoPrecise Antibodies Ltd. financial statements, including revenue, expenses, and profit
The total revenue of IPA for the last quarter is 4.33 M USD, and it's 3.46% lower compared to the previous quarter. The net income of Q3 24 is -15.15 M USD.
Q4 '16
Q1 '17
Q2 '17
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
−18.00 M
−12.00 M
−6.00 M
0.00
6.00 M
Total revenue
Gross profit
Operating income
Pretax income
Net income
Currency: USD
Q4 '16
Apr 2017
Q1 '17
Jul 2017
Q2 '17
Oct 2017
Q3 '17
Jan 2018
Q4 '17
Apr 2018
Q1 '18
Jul 2018
Q2 '18
Oct 2018
Q3 '18
Jan 2019
Q4 '18
Apr 2019
Q1 '19
Jul 2019
Q2 '19
Oct 2019
Q3 '19
Jan 2020
Q4 '19
Apr 2020
Q1 '20
Jul 2020
Q2 '20
Oct 2020
Q3 '20
Jan 2021
Q4 '20
Apr 2021
Q1 '21
Jul 2021
Q2 '21
Oct 2021
Q3 '21
Jan 2022
Q4 '21
Apr 2022
Q1 '22
Jul 2022
Q2 '22
Oct 2022
Q3 '22
Jan 2023
Q4 '22
Apr 2023
Q1 '23
Jul 2023
Q2 '23
Oct 2023
Q3 '23
Jan 2024
Q4 '23
Apr 2024
Q1 '24
Jul 2024
Q2 '24
Oct 2024
Q3 '24
Jan 2025
TTM
Total revenueYoY growth
4.15 M
+0.33%
4.26 M
+16.96%
4.53 M
+16.26%
4.60 M
+19.97%
4.76 M
+14.69%
3.84 M
−9.84%
4.49 M
−0.98%
4.33 M
−5.89%
17.42 M
−2.66 M
−2.80 M
−2.88 M
−2.76 M
−2.99 M
−2.57 M
−2.42 M
−2.45 M
−10.42 M
Gross profitYoY growth
1.49 M
—
1.46 M
—
1.65 M
+20.38%
1.84 M
+28.49%
1.77 M
+18.70%
1.28 M
−12.46%
2.07 M
+25.18%
1.88 M
+2.22%
7.00 M
−5.98 M
−4.59 M
−3.88 M
−4.31 M
−4.39 M
−4.76 M
−4.15 M
−4.20 M
−17.49 M
Operating incomeYoY growth
−4.48 M
−35.55%
−3.13 M
+59.80%
−2.23 M
+62.13%
−2.47 M
+27.28%
−2.61 M
+41.71%
−3.49 M
−11.34%
−2.08 M
+6.56%
−2.32 M
+6.28%
−10.49 M
132.12 K
262.27 K
318.91 K
−86.54 K
−11.25 M
−2.93 K
−159.64 K
−14.96 M
−26.37 M
Pretax incomeYoY growth
−4.35 M
−26.19%
−2.87 M
+62.29%
−1.91 M
+66.05%
−2.56 M
+24.97%
−13.87 M
−218.63%
−3.49 M
−21.58%
−2.24 M
−17.43%
−17.27 M
−575.49%
−36.86 M
566.14 K
196.33 K
−23.57 K
382.38 K
572.43 K
566.61 K
370.54 K
2.12 M
3.63 M
−3.79 M
−2.67 M
−1.93 M
−2.17 M
−13.29 M
−2.92 M
−1.87 M
−15.15 M
−33.23 M
Net incomeYoY growth
−3.79 M
−3.28%
−2.67 M
+63.36%
−1.93 M
+65.04%
−2.17 M
+37.61%
−13.29 M
−251.15%
−2.92 M
−9.30%
−1.87 M
+3.19%
−15.15 M
−596.70%
−33.23 M
−3.79 M
−2.67 M
−1.93 M
−2.17 M
−13.29 M
−2.92 M
−1.87 M
−15.15 M
−33.23 M
Basic earnings per share (Basic EPS)YoY growth
−0.15
+13.01%
−0.11
+63.83%
−0.08
+65.29%
−0.08
+39.66%
−0.49
−226.54%
−0.11
−0.94%
−0.07
+13.75%
−0.46
−447.09%
−1.13
Diluted earnings per share (Diluted EPS)YoY growth
−0.15
+13.01%
−0.11
+63.83%
−0.08
+65.29%
−0.08
+39.66%
−0.49
−226.54%
−0.11
−0.94%
−0.07
+13.75%
−0.46
−447.09%
−1.13
25.05 M
25.05 M
25.05 M
25.80 M
26.94 M
27.13 M
28.13 M
32.85 M
—
25.05 M
25.05 M
25.05 M
25.80 M
26.94 M
27.13 M
28.13 M
32.85 M
—
EBITDAYoY growth
−3.02 M
−17.19%
−2.01 M
+69.45%
−1.23 M
+74.25%
−1.50 M
+30.00%
−1.45 M
+51.97%
−2.47 M
−22.68%
−1.04 M
+15.15%
−1.33 M
+11.25%
−6.29 M
EBITYoY growth
−4.48 M
−35.55%
−3.13 M
+59.80%
−2.23 M
+62.13%
−2.47 M
+27.28%
−2.61 M
+41.71%
−3.49 M
−11.34%
−2.08 M
+6.56%
−2.32 M
+6.28%
−10.49 M
−8.63 M
−7.39 M
−6.76 M
−7.07 M
−7.37 M
−7.33 M
−6.57 M
−6.65 M
−27.91 M